Patents by Inventor Florian Paul Christian Binder

Florian Paul Christian Binder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TETRAZOLES
    Publication number: 20240101561
    Abstract: This invention relates to tetrazoles and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: October 14, 2020
    Publication date: March 28, 2024
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Uta Friederike LESSEL, Jens WILLWACHER
  • (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES
    Publication number: 20240092769
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Application
    Filed: June 30, 2023
    Publication date: March 21, 2024
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan George Mueller, Janet Rachel Nicholson, Achim Sauer
  • PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
    Publication number: 20240059675
    Abstract: The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: July 31, 2023
    Publication date: February 22, 2024
    Inventors: Jens WILLWACHER, Florian Paul Christian BINDER, Georg DAHMANN, James Young Soo YANG HAMILTON, Sandra Ruth HANDSCHUH, Sophia Astrid REINDL
  • Tetrazole derivatives as TRPA1 inhibitors
    Patent number: 11891403
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: February 6, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Jens Willwacher
  • Tetrazole derivatives as TRPA1 inhibitors
    Patent number: 11884652
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: January 30, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Martin Thomas Fleck, Jens Willwacher
  • 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as TRPA1 inhibitors
    Patent number: 11884681
    Abstract: The present disclosure provides certain 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 30, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder
  • Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors
    Patent number: 11878981
    Abstract: The present disclosure provides certain substituted 1,2,4-oxadiazole derivatives of the below formula (I) that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 23, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Georg Dahmann, Martin Thomas Fleck, Annekatrin Charlotte Heimann, Thorsten Oost
  • Uracil derivatives as TRPA1 inhibitors
    Patent number: 11858921
    Abstract: The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Grant
    Filed: April 13, 2022
    Date of Patent: January 2, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Martin Thomas Fleck, Jens Willwacher
  • TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS
    Publication number: 20230257395
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 19, 2023
    Publication date: August 17, 2023
    Inventors: Florian Paul Christian BINDER, Thomas Martin FLECK, Jens WILLWACHER
  • (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
    Patent number: 11725004
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: August 15, 2023
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • Tetrazole derivatives as TRPA1 inhibitors
    Patent number: 11661430
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Florian Paul Christian Binder, Thomas Martin Fleck, Jens Willwacher
  • Tetrazole derivatives as TRPA1 inhibitors
    Patent number: 11661427
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing the same.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: May 30, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Jens Willwacher
  • Thienopyrimidones
    Patent number: 11578080
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: February 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Uta Friederike Lessel, Jens Willwacher
  • IMIDAZO[4,5-D]PYRIDAZINONYL DERIVATIVES AS TRPA1 INHIBITORS
    Publication number: 20220340580
    Abstract: The present disclosure provides certain imidazo[4,5-d]pyridazinonyl derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Florian Paul Christian BINDER, Georg DAHMANN, Martin Thomas FLECK, Annekatrin Charlotte HEIMANN, Thorsten OOST
  • 3H,4H,5H,6H,7H-PYRIMIDO[4,5-B][1,4]OXAZINE-4,6-DIONE DERIVATIVES AS TRPA1 INHIBITORS
    Publication number: 20220340593
    Abstract: The present disclosure provides certain 3H,4H,5H,6H,7H-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER
  • URACIL DERIVATIVES AS TRPA1 INHIBITORS
    Publication number: 20220340552
    Abstract: The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Florian Paul Christian BINDER, Martin Thomas FLECK, Jens WILLWACHER
  • 3H,4H-THIENO[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES AS TRPA1 INHIBITORS
    Publication number: 20220340590
    Abstract: The present disclosure provides certain 3H,4H-thieno[2,3-d]pyrimidin-4-one derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 27, 2022
    Inventors: Florian Paul Christian BINDER, Jens WILLWACHER, Martin Thomas FLECK
  • NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES
    Publication number: 20220135554
    Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
    Type: Application
    Filed: August 10, 2021
    Publication date: May 5, 2022
    Inventors: Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer
  • TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS
    Publication number: 20220112202
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Jens WILLWACHER
  • TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS
    Publication number: 20220112210
    Abstract: The present disclosure provides certain tetrazole derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
    Type: Application
    Filed: October 13, 2021
    Publication date: April 14, 2022
    Inventors: Florian Paul Christian BINDER, Thomas Martin FLECK, Jens WILLWACHER